NCT06772753

Investigation of Psychedelic Effects in Psychoactive Substances

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 25 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.

Conditions

• Psychedelic Effects in Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Placebo	inactive substance
DRUG	Psilocybin	active comparator for psychedelic effects
DRUG	Ketamine	psychoactive substance
DRUG	Dextromethorphan (DXM)	psychoactive substance
DRUG	Dimethyltryptamine (DMT)	psychoactive substance
DRUG	Methylenedioxymethamphetamine (MDMA)	psychoactive substance
DRUG	Tetrahydrocannabinol (THC)	psychoactive substance

Timeline

• Start date: 2025-02-05
• Primary completion: 2027-06-01
• Completion: 2027-12-01
• First posted: 2025-01-14
• Last updated: 2026-02-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study